Opdivo nivolumab: Updated Phase I/II data

Updated data from a cohort of 78 patients with metastatic urothelial cancer in the open-label, international Phase I/II CheckMate -032 trial showed that 3 mg/kg IV Opdivo every 2 weeks led to a median OS of 9.72 months and a 1-year OS rate of 45.6%. Data were presented at the American Society of Clinical Oncology meeting in Chicago. Bristol-Myers has previously reported data from the trial (see BioCentury, Aug. 3, 2015; May 30, 2016 & June 6, 2016). ...